Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 12 , ISSUE 3 ( May-June, 2020 ) > List of Articles


Efficacy and Safety of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder

Ambreen Qureshi, Sajad Ahmad Malik, Malik Suhail Ahmad

Citation Information : Qureshi A, Malik SA, Ahmad MS. Efficacy and Safety of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder. J South Asian Feder Obs Gynae 2020; 12 (3):178-181.

DOI: 10.5005/jp-journals-10006-1800

License: CC BY-NC 4.0

Published Online: 10-02-2021

Copyright Statement:  Copyright © 2020; The Author(s).


Aims and objectives: The main aims and objectives of this study were to study efficacy, safety, and quality of life with combination anticholinergics and desmopressin compared to anticholinergics alone. Materials and methods: A total of 92 patients were randomly assigned to two groups. Patients were randomly assigned to receive 5 mg of solifenacin (group I) or 5 mg of solifenacin and 0.2 mg of desmopressin (group II) for 1 month. The patients were followed for 2 weeks to look for undesired side effect and then at 1 month with 3-day voiding diary. IIQ-7 questionnaire score was used to assess changes in voiding symptoms and quality of life. Results: Out of 42 in group I and 50 in group II, one patient in group I and three patients in group II did not follow and were excluded from the study. Baseline parameters between the two groups were statistically similar. Posttreatment parameters such as mean number of voids in first 8 hours decrease from 5.53 to 3.48 in group I vs 5.7 to 2.13 in group II, p valve <0.01. The mean number of urgency episodes in first 8 hours in group I decreased from 4.23 to 3.11 vs 4.68 to 2.29 in group II, p valve <0.01. The mean number of nocturnal voids in group I decreased from 3.55 to 2.48 vs 3.35 to 1.34 in group II, p valve <0.01. The mean IIQ-7 score in group I decreased from 51.10 to 32.8 vs 54.63 to 18.82 in group II, p valve <0.01. Differences were statistically significant. There was statistically insignificant change in serum sodium level posttreatment between group I and group II. Conclusion: Combination of desmopressin and anticholinergics was more effective and safe than anticholinergics alone in the treatment of female patients with overactive bladder. Therefore, desmopressin combined with anticholinergics could be considered feasible and safe method for relief of symptoms in female patients with overactive bladder. However, larger and long-term studies for proper evaluation are warranted.

  1. The standardisation of terminology of lower urinary tract function; report from standardisation sub-committee of international continence society. Neurol Urodynam 2002;21(2):167–178. DOI: 10.1002/nau.10052.
  2. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50(6):1306–1314. DOI: 10.1016/j.eururo.2006.09.019discussion 1306-1314.
  3. Influence of type of nocturia and lower urinary tract symptoms on therapeutic outcome in women treated with desmopressin. Korean J Urol 2013;54(2):95–99. DOI: 10.4111/kju.2013.54.2.95.
  4. The prevalence and causes of nocturia. J Urol 2010;184(2):440–446. DOI: 10.1016/j.juro.2010.04.011.
  5. Overactive bladder. Korean J Urol 2007;48(12):1191–1208. DOI: 10.4111/kju.2007.48.12.1191.
  6. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104(9):988–993. DOI: 10.1111/j.1471-0528.1997.tb12054.x.
  7. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol 2017;35(5):827–838. DOI: 10.1007/s00345-016-1908-1.
  8. Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Contine Prog Women Res Group Neurou Urodyn 1995;14(2):131–139. DOI: 10.1002/nau.1930140206.
  9. Model of peripheral autonomous modules and a myovesical plexus in normal and overactiver bladder. Lancet 2001;358(9279):401–403. DOI: 10.1016/S0140-6736(01)05549-0.
  10. Desmopressin, as a “designer-drug,” in the treatment of overactive bladder syndrome. Neurourol Urodyn 2009;28(1):40–46. DOI: 10.1002/nau.20613.
  11. Effect of desmopressin with anticholinergics in female patients with overactive bladde. Korean J Urol 2011;52(6):396–400. DOI: 10.4111/kju.2011.52.6.396.
  12. Prevalence and burden of overactive bladder in united states. World J Urol 2003;20(6):327–336. DOI: 10.1007/s00345-002-0301-4.
  13. Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study. Low Urin Tract Symptoms 2017;10(3):221–230. DOI: 10.1111/luts.12169.
  14. Efficacy and safety of low dose desmopressin orally disintegrating tablet in womwn with nocturea: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol 2013;190(3):958–964. DOI: 10.1016/j.juro.2013.02.037.
  15. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006;25(2):105–109. DOI: 10.1002/nau.20168.
  16. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2007;2(3):232–238. DOI: 10.2174/157488607781668891.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.